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Once considered a waning disease, the burden of tuberculosis (TB) has 
increased around the world over the last decades. Today, TB is the leading 
cause of mortality associated with a single infectious pathogen [1]. Although 
treatment regimens as suggested by the World Health Organization (WHO) 
result in survival rates of 95% under trial conditions [2], the mortality of TB-
associated critical illness remains unacceptably high, and exceeds 50% in 
many cohorts [3]. This makes Mycobacterium tuberuclosis one of the 
deadliest causes of sepsis, a fact often not recognized by many clinicians in 
high-income countries. The exponential increase in mortality between non-
critically and critically ill patients with active TB disease suggests that anti-
TB treatment regimens may be inadequate once organ dysfunction and 
sepsis have occurred. This concise review focuses on novel pharmacokinetic 
considerations and suggests a potential novel approach to anti-TB treatment 
in the critically ill patient. 
 
Who should be treated? 
Timely initiation of anti-TB therapy is essential for treatment success, 
particularly in patients with a high disease severity [3]. This crucially 
depends on early recognition of at-risk populations and rapid confirmation of 
the diagnosis. Risk factors for active TB disease broadly include poor living 
conditions, previous infection or contact with TB (e.g. people living in or 
originating from endemic regions, prisoners, healthcare workers), 
immunosuppression (e.g. human immunodeficiency virus (HIV) infection, 
immunosuppressive therapy including biologics, alcoholism), extremes of 
age, and medical conditions known to increase the risk for TB (e.g. COPD, 
silicosis, diabetes mellitus, malnutrition). Acute respiratory failure, altered 
mental state, septic shock and multiple organ dysfunction are the most 
common causes of critical illness and intensive care unit admission of 
patients with TB. Rapid TB tests based on nucleic acid amplification 
techniques (e.g. GeneXpert MTB/RIF) are sensitive and specific to diagnose 
active TB disease in both HIV-negative and -positive patients within a few 
hours [4]. Simultaneously, these tests can identify multi-drug resistant 
(MDR) strains. 
 
What anti-TB treatment regimen should be started in critically ill 
patients? 
For both adults and children, the WHO recommends an intensive treatment 
regimen (rifampicin+isoniazid+ethambutol+pyrazinamide) for two months, 
followed by a continuation regimen (rifampicin+isoniazid) for four to seven 
months [5]. Treatment regimens for MDR TB include at least four second line 
anti-TB drugs [5]. 
 
Pharmacokinetic considerations in critically ill patients 
Although only limited data on pharmacokinetic changes of anti-TB drugs in 
critically ill patients have been published, those available consistently report 
inadequate anti-TB drug levels. In a South African population, therapeutic 
drug levels were detected in <30% of critically ill patients when a standard 
drug regimen was given as a fixed drug combination dose via a nasogastric 
tube [6]. Multiple factors alter pharmacokinetics during critical illness [7]. 
Intestinal drug absorption is commonly delayed or altered by gastroparesis, 
intestinal paralysis, pharmacological ulcer prophylaxis, and changes in the 
gut microbiome. Fluid accumulation increases the volume of distribution of 
anti-TB drugs with consequent reduction in serum and tissue levels. In 
addition, glomerular hyperfiltration [7] resulting in augmented renal 
clearance of anti-TB drugs, genetic variations in drug metabolization (e.g. 
isoniazid), and poor penetration into infected compartments [8] are likely to 
contribute to sub-therapeutic levels at the site of TB infection. Such sub-
therapeutic anti-TB drug levels have been associated with treatment failure 
and increased mortality [9,10]. 
 
A novel approach to anti-TB treatment in critically ill patients 
In view of the aforementioned pharmacokinetic changes, it appears 
pragmatic to modify the initial anti-TB treatment in critically ill patients to 
optimize and achieve therapeutic blood levels of anti-TB drugs (Figure 1). 
During the phase of critical illness, anti-TB drugs should be administered 
intravenously and probably at higher dosages than recommended by current 
guidelines. Although rifampicin, the drug with the highest sterilizing TB 
activity, is available in an intravenous formulation, it and other standard 
anti-TB drugs are not universally available in this form. Consequently, 
modified regimens including intravenous formulations of alternative and 
highly effective anti-TB drugs (e.g. rifampicin+moxifloxacin+amikacin) may 
be administered. Empirical intravenous fluoroquinolone use improved the 
survival of critically ill patients admitted for pulmonary TB [11]. Several 
studies have reported that higher than usual doses of anti-TB drugs (e.g. 
rifampicin up to 35 mg/kg/d [12]) were safe, reduced the time to culture 
conversion in liquid media, and may be associated with better survival in 
patients with severe disease [12,13]. A recent large trial evaluating an 
intensified regimen including higher-dose rifampicin (15 mg/kg/d) and 
levofloxacin (20 mg/kg/d) for the first eight weeks, however, failed to confirm 
these results in adults with TB meningitis [14]. Since only 17.4% of study 
patients presented with a high disease severity, the implications of this trial 
for the management of critically ill patients remain unclear. The use of 
therapeutic drug monitoring (TDM) has also been advocated to optimize 
dosing of anti-TB drugs relative to minimum inhibitory concentrations 
(MICs) [15]. Critical drawbacks of such a strategy are the restricted 
availability of this useful adjunct in many endemic regions, and the fact that 
MICs are only known after culture and resistance testing. In all critically ill 
patients and especially in those with MDR TB disease, infectious disease 
specialist should assist with the empirical selection and dosing of anti-TB 
drugs, as well as their interactions with other drugs (e.g. HIV therapy). 
During recovery from critical illness, high-dose intravenous anti-TB therapy 
can be switched to currently recommended enteral, fixed dose regimens 
(Figure 1). The time point for this transition is clinically highlighted and 
determined by improvement of organ function, in particular gastrointestinal 
function (e.g. full tolerance of enteral feeds), and reversal of fluid 
accumulation. 
 
 
Conclusions 
TB remains an enormous healthcare problem with a billion lives having been 
consumed over the last two centuries. Scores of critically ill patients with TB 
are encountered globally on a daily basis. It is incumbent on intensive care 
practitioners to be aware of the problem and focus on efforts to address the 
unacceptably poor outcomes associated with this disease entity. Although 
various factors may influence, optimizing therapeutic approaches may very 
well limit “consumption” in critically ill patients with TB. We eagerly and 
excitedly await further work in this sphere! 
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